Tarsus Pharmaceuticals, Inc. (NASDAQ:TARS) Given Consensus Recommendation of “Buy” by Brokerages

Tarsus Pharmaceuticals, Inc. (NASDAQ:TARS) has been assigned an average recommendation of “Buy” from the six analysts that are presently covering the company, MarketBeat.com reports. One investment analyst has rated the stock with a hold recommendation, four have given a buy recommendation and one has issued a strong buy recommendation on the company. The average twelve-month target price among analysts that have issued a report on the stock in the last year is $54.20.

A number of equities research analysts have recently commented on the stock. The Goldman Sachs Group upped their target price on shares of Tarsus Pharmaceuticals from $36.00 to $41.00 and gave the company a “neutral” rating in a report on Friday, November 15th. Oppenheimer upped their price objective on Tarsus Pharmaceuticals from $63.00 to $65.00 and gave the company an “outperform” rating in a research note on Thursday, November 14th.

Tarsus Pharmaceuticals Stock Performance

Shares of Tarsus Pharmaceuticals stock opened at $55.00 on Tuesday. The firm’s fifty day simple moving average is $48.24 and its 200-day simple moving average is $35.80. Tarsus Pharmaceuticals has a 12 month low of $18.99 and a 12 month high of $56.77. The stock has a market capitalization of $2.10 billion, a price-to-earnings ratio of -14.44 and a beta of 1.04. The company has a debt-to-equity ratio of 0.30, a current ratio of 5.42 and a quick ratio of 5.38.

Institutional Inflows and Outflows

Several large investors have recently added to or reduced their stakes in the company. Cowen AND Company LLC increased its position in Tarsus Pharmaceuticals by 3.5% during the 2nd quarter. Cowen AND Company LLC now owns 2,197,385 shares of the company’s stock worth $59,725,000 after purchasing an additional 74,855 shares during the period. Jennison Associates LLC boosted its stake in shares of Tarsus Pharmaceuticals by 47.2% in the third quarter. Jennison Associates LLC now owns 2,178,580 shares of the company’s stock valued at $71,653,000 after buying an additional 698,712 shares in the last quarter. Assenagon Asset Management S.A. grew its holdings in Tarsus Pharmaceuticals by 7.3% during the third quarter. Assenagon Asset Management S.A. now owns 1,141,247 shares of the company’s stock worth $37,536,000 after acquiring an additional 77,825 shares during the period. Ikarian Capital LLC raised its position in Tarsus Pharmaceuticals by 28.7% in the third quarter. Ikarian Capital LLC now owns 1,030,277 shares of the company’s stock worth $33,886,000 after acquiring an additional 230,000 shares in the last quarter. Finally, Geode Capital Management LLC lifted its holdings in Tarsus Pharmaceuticals by 8.1% in the third quarter. Geode Capital Management LLC now owns 835,790 shares of the company’s stock valued at $27,494,000 after acquiring an additional 62,555 shares during the period. 90.01% of the stock is owned by hedge funds and other institutional investors.

Tarsus Pharmaceuticals Company Profile

Tarsus Pharmaceuticals, Inc, a commercial stage biopharmaceutical company, focuses on the development and commercialization of novel therapeutic candidates for eye care in the United States. The company's lead product candidate is XDEMVY, a novel therapeutic for the treatment of blepharitis caused by the infestation of Demodex mites, as well as to treat meibomian gland disease.